Amicus Therapeutics, Inc.
FOLD
Rankning i aktier
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Aktiekurs
$14.49
Senast synkroniserad: 2026-04-27
Marknadsvärde
$4.55B
Förändring (1 dag)
0.00%
Förändring (1 år)
80.22%
Land
US
Handel Amicus Therapeutics, Inc. (FOLD)
Kategori
Healthcare
EPS för Amicus Therapeutics, Inc. (FOLD)
EPS per December 2025 TTM: $-0.09
Enligt Amicus Therapeutics, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-0.09. Vid slutet av 2023 hade bolaget ett EPS på $-0.51, en minskning jämfört med EPS från 2022 som var $-0.82.
EPS-historik för Amicus Therapeutics, Inc. från 2003 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-0.09 | -50.83% |
| 2024 | $-0.18 | -64.71% |
| 2023 | $-0.51 | -37.80% |
| 2022 | $-0.82 | -10.87% |
| 2021 | $-0.92 | -14.02% |
| 2020 | $-1.07 | -27.70% |
| 2019 | $-1.48 | -21.28% |
| 2018 | $-1.88 | 1.62% |
| 2017 | $-1.85 | 24.16% |
| 2016 | $-1.49 | 24.17% |
| 2015 | $-1.20 | 29.03% |
| 2014 | $-0.93 | -19.83% |
| 2013 | $-1.16 | 8.41% |
| 2012 | $-1.07 | -16.41% |
| 2011 | $-1.28 | -35.35% |
| 2010 | $-1.98 | 582.76% |
| 2009 | $-0.29 | -83.43% |
| 2008 | $-1.75 | -43.73% |
| 2007 | $-3.11 | -95.06% |
| 2006 | $-62.97 | 29.33% |
| 2005 | $-48.69 | 70.01% |
| 2004 | $-28.64 | 30.12% |
| 2003 | $-22.01 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -19,670.62% |
US
|
|
| $-7.98 | 8,916.95% |
US
|
|
| $-5.29 | 5,877.40% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -31,444.63% |
NL
|
